Show simple item record

dc.contributor.authorÇEVIK, Serdar
dc.contributor.authorKitis, SERKAN
dc.contributor.authorEVRAN, Şevket
dc.contributor.authorAKKAYA, Enes
dc.contributor.authorTOSUNER, ZEYNEP
dc.contributor.authorHANIMOGLU, Hakan
dc.date.accessioned2019-10-05T14:39:54Z
dc.date.available2019-10-05T14:39:54Z
dc.date.issued2018-04-01
dc.identifier.urihttps://hdl.handle.net/20.500.12645/4414
dc.description.abstractBackground: Glioblastoma multiforme (GBM) is the most common primary brain tumor characterized with poor prognosis and short survival. In addition to the standard treatment protocols, targeted molecular treatment options are under trial. In the recent trials, erythropoietin and erythropoietin receptor were found to be linked with the progression of GBM cells. Aim: In this study, we compared the expression of EPOR with survival in GBM patients with mortality. Materials and Methods: Twenty‑six patients operated for GBM in 2012–2014 were enrolled in this study. Tumor tissues were stained with EPOR, epidermal growth factor receptor, vascular endothelial growth factor, and assigned as (1+), (2+), and (3+) according to their immunohistochemical staining levels. The average postoperative follow‑up time was 9.3 months. Kaplan–Meier’s survival test and Spearman’s correlation test were used in statistical analysis. Results: EPOR 1(+) stained group showed a median survival of 8 months (95% confidence interval [CI]: 0.954–15.046). EPOR 2(+) stained group showed a median survival of 6 months (95% CI: 2.901–9.090) EPOR 3(+) stained group showed a median survival of 2 months (95% CI: 0.400–3.600). (Kaplan–Meier P = 0.002). Conclusion: These results portrayed that EPOR staining levels were inversely proportional with average survival time. In the future, specific inhibitors of this molecule could be used to form a novel treatment option for GBM.en
dc.language.isoen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectÇEVIK S., Kitis S., EVRAN Ş., AKKAYA E., TOSUNER Z., HANIMOGLU H., -The relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients.-, Nigerian journal of clinical practice, cilt.21, ss.502-506, 2018
dc.titleThe relationship of erythropoietin receptor expression and prognosis in glioblastoma multiforme patients.
dc.typeArticle
local.avesis.response4284
local.article.journalnamePREHOSPITAL AND DISASTER MEDICINE
local.org.facultyTıp Fakültesi
dc.identifier.wosWOS:000429375500016
dc.identifier.scopus85045146319
dc.identifier.doi10.4103/njcp.njcp_126_17
dc.identifier.pubmed29607865
local.publication.isinternational1
dc.contributor.institutionauthorKİTİŞ, SERKAN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record